SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-120526
Filing Date
2020-11-02
Accepted
2020-11-02 16:14:31
Documents
6
Period of Report
2020-10-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2034714d1_8k.htm 8-K 21659
2 EXHIBIT 1.1 tm2034714d1_ex1-1.htm EX-1.1 234454
3 EXHIBIT 99.1 tm2034714d1_ex99-1.htm EX-99.1 7317
4 EXHIBIT 99.2 tm2034714d1_ex99-2.htm EX-99.2 6789
5 GRAPHIC tm2034714d1_ex99-1img001.jpg GRAPHIC 3584
6 GRAPHIC tm2034714d1_ex99-2img01.jpg GRAPHIC 12108
  Complete submission text file 0001104659-20-120526.txt   293364
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 201280612
SIC: 2836 Biological Products, (No Diagnostic Substances)